Latest Content

The FDA has approved durvalumab plus FLOT for the treatment of patients with resectable gastric or gastroesophageal junction adenocarcinoma.

Emily Shelby, MSN, FNP-C, emphasized that referrals to other specialties is key to managing heavily pretreated patients with metastatic colorectal cancer.

Pembrolizumab plus paclitaxel with or without bevacizumab boosted survival in patients with platinum-resistant, recurrent ovarian cancer.

Kennon McCollum, DNP, explains how multiday ES-SCLC chemotherapy regimens heighten myelosuppression risk and drive dose delays.

The FDA has approved intravenous or subcutaneous pembrolizumab combined with enfortumab vedotin-ejfv in the neoadjuvant and adjuvant MIBC settings.

Elizabeth Hubert, APRN, explains how to treat patients receiving luspatercept for low-risk myelodysplastic syndromes.

The addition of atezolizumab to BCG did not yield improved EFS compared with BCG alone in patients with high-risk non–muscle-invasive bladder cancer.

The FDA has converted its accelerated approval to a standard one for tarlatamab in extensive-stage small cell lung cancer.

Germline and somatic testing can inform treatment and family risk up front, but NGS is often held for recurrence, explained Courtney R. Arn, APRN-CNP.

The FDA granted standard approval to epcoritamab monotherapy and epcoritamab plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma.

Nivolumab displayed significant RFS benefit compared with ipilimumab in patients with resected stage IIIB to IIIC or IV melanoma.

Gabriel Schwartz, MSN, NP, explains how mechanisms of action determine the safety of systemic treatments in metastatic colorectal cancer post chemotherapy.